DNA methylation contributes to carcinogenesis by silencing key tumor suppressor genes. Here we report an ultrasensitive and reliable nanotechnology assay, MSqFRET, for detection and quantification of DNA methylation. Bisulfite modified DNA is 5 subjected to PCR amplification with primers that would differentiate between methylated and unmethylated DNA. Quantum dots are then used to capture PCR amplicons and determine the methylation status via fluorescence resonance energy transfer (FRET).
Introduction
Aberrant DNA hypermethylation is observed at classic tumor-suppressor genes, which are known to be genetically mutated and cause inherited forms of cancer (Jones and Baylin 2002) . Tumor cells display a larger number of genes inactivated by promoter hypermethylation than by genetic mutations (Schuebel et al. 2007 ). Furthermore, these 5 abnormal epigenetic changes appear to be an early event that precedes detection of genetic mutations (Esteller et al. 1999; Feinberg and Tycko 2004; Yamada et al. 2005 ).
Thus, detection of promoter hypermethylation is a valuable tool for early diagnosis of cancer, monitoring tumor behavior, as well as measuring response of tumors to targeted therapy (Brock et al. 2008; Esteller et al. 2000; Gore et al. 2006b ). 10
The number of tools available to assess DNA methylation demonstrates the extensive interest that has been invested in understanding the role of epigenetics in carcinogenesis (Laird 2003) . One of the more common techniques used for the detection of methylation is methylation-specific PCR (MSP) (Herman et al. 1996) . The technique relies on sodium bisulfite treatment of DNA which converts unmethylated 15 cytosines to uracils, while leaving methylated cytosines unaffected. The modified sequences are then amplified with specific primers, and the amplified products are identified using gel electrophoresis. However, this standard MSP approach offers only qualitative analysis and cannot discern relative amounts of methylation. Although realtime PCR-based MSP methods (Eads et al. 2000; Lo et al. 1999 ) enable quantitative 20 analysis, they may lack the sensitivity for direct screening of challenging samples, such as sputum, where the DNA from tumor cells is minimal, thereby requiring a Cold Spring Harbor Laboratory Press on September 29, 2017 -Published by genome.cshlp.org Downloaded from nested PCR approach Brandes et al. 2005; Kim et al. 2007; Machida et al. 2006 ).
Methylation-specific quantum dot Fluorescence Resonance Energy Transfer
(MS-qFRET) combines the high specificity of MSP and the high sensitivity and simplicity of the quantum dot FRET (QD-FRET) technology . MS-5 qFRET facilitates a straightforward approach for both a qualitative and quantitative detection of methylated DNA, as well as allowing detection of low-abundance methylated DNA. The sensitivity of the MS-qFRET is first examined here, followed by a demonstration of its ability to quantify methylation, both in cell lines, as well as in Myelodysplastic Syndrome (MDS) patient samples. The advantages of MS-qFRET are 10 also highlighted by its capability of multiplexing reactions and its potential application for high throughput screening. Finally, the sensitivity of this technique is validated in patient sputum samples that contain very low concentrations of DNA.
Results 15
In MS-qFRET, the bisulfite-treated DNA is amplified through PCR, wherein the forward primer is biotinylated and the reverse primer is labeled with an organic fluorophore ( Fig. 1) . Next, streptavidin-conjugated quantum dots (QDs) are introduced to capture the labeled PCR products via streptavidin-biotin binding, bringing the QDs (serving as donors) and fluorophores (serving as acceptors) in close proximity allowing FRET to 20 occur. Finally, PCR products are detected by emissions of fluorophores accompanied by quenching of QDs. Spectral information is processed to determine the level of DNA methylation.
Cold Spring Harbor Laboratory Press on September 29, 2017 -Published by genome.cshlp.org Downloaded from Feasibility of MS-qFRET. To examine the background noise level of MS-qFRET, control experiments were conducted using in-vitro methylated DNA (IVD) and unmethylated DNA (Normal lymphocytes, NL) with methylation-specific primers for the CDKN2a promoter (Table 1) . Using a fluorospectrometer, MS-qFRET detected PCR products as early as 8 cycles of amplification with starting quantities of DNA typical for 5 MSP (150 ng) (Herman et al. 1996) (Fig. 2A) . Signal obtained from MS-qFRET for methylated product after 8 cycles of amplification was significantly higher than that of the water control. The purpose of such early detection was to characterize the QD-FRET sensor and demonstrate that the extremely low background noise from QD-FRET allowed for detection after just few cycles of amplification. In addition, early 10 detection allowed for increased throughput as well as the ability to quantify in the loglinear phase of PCR amplification. In contrast, conventional gel or real-time based MSP methods (Eads et al. 2000; Fackler et al. 2004 ) generally required amplification of > 20 cycles in order to detect the presence of amplicons (Fig. 2B, data not shown) .
In order to analyze the analytical sensitivity of MS-qFRET, we used a confocal 15 fluorescence spectroscope sensitive even to single-molecule fluorescence . IVD was serially diluted in NL DNA (150 ng) and subject to MS-qFRET with 40 cycles of amplification. As seen in Figure 2C , each Cy5 peak seen (red) is the FRETinduced fluorescence burst associated with labeled-MSP products that is linked to a single QD passing through the focal detection volume of the confocal spectroscopy 20 setup (burst count). Figure 2D plots the burst counts for the entire time duration (3 separate runs of 100 s) for 1/10, 1/100, 1/1,000 and 1/10,000 and 0 methylated/ unmethylated CDKN2a alleles (IVD/NL), which corresponds to 5000, 500, 50 and 5
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Triplicates of the same reaction samples were used in order to capture the variability and reproducibility of the detection technology. FRET signals were observed using as little as 15 pg (~ 5 genomic equivalents) of methylated DNA (IVD) in an excess of 150 5 ng of unmethylated DNA (NL) which is distinctly above the signal observed with only NL DNA (Fig. 2D ) . These results indicate that MS-qFRET is sensitive to detect as little as 5 copies of methylated DNA when combined with a sensitive detection setup.
The true sensitivity however is dependent on various factors including PCR reaction conditions, efficiency of primers, product size and sampling effects, especially when 10 diluting to 5 copies per reaction. Any variability arising from sampling will be reflected in the amount of PCR product, and therefore the burst counts. To account for such sample variability, we performed the burst count analysis of PCR reactions that used templates from triplicates of separate serial dilutions. An increase in variance of the burst counts is observed with increasing dilutions (Supplementary Fig. 1 ). This is 15 consistent with what would be expected at high dilutions, especially in the range of 5 copies per reaction wherein 43.1% of the reactions will have less than 5 copies per reaction and 38.3% will have more than 5 copies per reaction. Most importantly, signal observed from MS-qFRET from the 1:10,000 dilution samples indicates a clear difference from the NL control. Together, the results shown in Figure 2 Fig. 2, Fig. 3, Fig. 4 ). Since most amplicon sizes lie within this range, MS-qFRET is easily adaptable to current MSP techniques in analyzing numerous genes. Notably, the background level was minimal in the presence of only NL, while strong FRET signals were clearly observed in the presence 5 of IVD, when amplified with methylation-specific primers (Fig. 2C, D) .
Quantification of Methylation. The capability of PCR detection at the early log-linear stage makes quantifying DNA methylation possible. To examine the quantitative accuracy of MS-qFRET, IVD and NL were mixed in different ratios, and analyzed using 10 a fluorospectrometer after 16 cycles at the CDKN2a promoter with methylation-specific primers. As shown in Figure 3A , with an increasing amount of input methylated DNA in the mixture (with a fixed total DNA concentration), there is a corresponding increase in the intensity of the acceptor (Cy5) emission, and donor (QD605) quenching. Figure   3B shows a linear correlation between the normalized FRET efficiency, herein referred 15 to as the q-score (see Methods), and the input methylation level. Standard error bars are computed from 5 separate experiments. By including a methylated or unmethylated dilution series in every assay with a known total input DNA, a standard curve can be created to quantify methylation of unknown samples from the q-score. agent. Reversal of methylation in the colorectal cancer cell line, RKO, was quantified at specific time points after treatment with 5-aza-2'-deoxycytidine (DAC). Figure 3C is from triplicate data and shows a 10 to 20 percent decrease in methylation at CDKN2a within 24 to 36 hours with maximal reversal seen at 60 hours post-treatment. Since DNA replication is necessary for incorporation of DAC into DNA, reversal of 5 methylation may be best observed only after inhibition of DNA methyltransferases due to cell cycling. The low amount of methylation reversal in the initial 24 to 36 hours could be attributed to the 22 hour doubling time for RKO cells. These results are consistent with methylation reversal studies using Ms-SNUPE (Bender et al. 1999) .
To demonstrate the quantitative ability of MS-qFRET directly in a clinical 10 setting, reversal of methylation at the CDKN2b promoter (Christiansen et al. 2003; Daskalakis et al. 2002; Herman et al. 1997; Quesnel et al. 1998; Shimamoto et al. 2005 ) was analyzed on bone marrow aspirate samples from patients with MDS who received epigenetic therapy as part of an Institutional Review Board approved clinical trial. Patients were treated with combination therapy using both 5-azacytidine (Vidaza) 15 and MS-275 (Entinostat), a histone deacetylase inhibitor. Bone marrow aspirate samples were obtained pre-treatment (day 0), day 14 and day 29 of the first cycle of combination therapy. Gel electrophoresis is a common means to monitor the response to such therapy (Christiansen et al. 2003; Fahrner et al. 2002; Gore et al. 2006a ).
However, after many cycles of PCR amplification, the data does not remain 20 quantifiable and resolving methylation becomes challenging. MS-qFRET allows for computing such differences in methylation by measuring methylation at the early stage of amplification. As shown for 6 patients ( Fig. 3D) , MS-qFRET is used for detecting and tracking methylation changes for each patient in a quantitative manner, with the day 0 sample being the "control" for the following sample time points (day 15 and day 29) for each patient. Results obtained from 16 cycle analysis of MS-qFRET were consistent with trends observed from 40 cycles of real-time PCR (Supplementary Fig.   2 ). These data highlight that individual patients have unique responses to epigenetic 5 agents in vivo and that these subtle changes are easily quantifiable using MS-qFRET. Comparison of these results to detection with MS-qFRET was performed in a blinded fashion. A representative spectroscopic trace for two patients with differing methylation is shown in Figure 4B , where a prominent peak seen at 670 nm (Cy5 emission)
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indicates the presence of methylated PYCARD promoter. In this case, since higher PCR cycles were used, normalized FRET efficiency (En) (see Methods) for all 20 patients is shown in Figure 4C , which indicates that the same three samples found to be methylated at PYCARD by nested MSP were also detected using MS-qFRET. For 5 CDKN2a, unmethylated bands were detected with both standard MSP and the nested MSP in all 20 patients. While 13 patients were found to have methylated CDKN2a using MS-qFRET, 12 of the same patients also showed methylation using the nested approach, but none were methylated by standard MSP (Supplementary Fig. 4) . The difference between nested and MS-qFRET in one patient sample can most likely be 10 attributed to sampling effects seen with the presence of rare methylated DNA ). For CDKN2b, both nested and MS-qFRET techniques demonstrated that all patients were unmethylated, suggesting that the enhanced sensitivity of MS-qFRET did not result in false positives ( Supplementary Fig. 4 ).
Together, these results illustrate the sensitivity of MS-qFRET in detecting very low 15 amounts of methylation in patient samples. The ability to detect methylation in these clinical samples without the use of a nested approach could make this a promising approach for lung cancer screening.
Discussion 20
Common approaches to detect gene specific methylation include MSP, nested MSP and real time PCR which all rely on bisulfite converted DNA (Eads et al. 2000; Herman et al. 1996; Machida et al. 2006 ). For samples with low concentrations of DNA, nested MSP is frequently utilized, and requires numerous amplification cycles (i.e., greater than 40) (Machida et al. 2006 ). Drawbacks to the nested approach are that it can yield false positive results and requires setting up more than one PCR reaction. Additionally, real-time PCR (either SYBR Green or Taqman) offers a quantification method, but is limited by inherent background fluorescence. MS-qFRET overcomes these limitations 5 in a simple endpoint detection format. The unique optical properties of QDs, such as narrow emission bands and large Stokes shift render them as ideal FRET donors. This allows minimal fluorescent cross-talk and direct excitation of acceptors (Medintz et al. 2003; Zhang et al. 2005) and permits the design of FRET-based assays with extremely low fluorescent background noise. MS-qFRET combines the advantages of 10 the QD-FRET system with MSP. This report characterizes the feasibility and analytical sensitivity of MS-qFRET; demonstrates its ability to detect amplicons with few amplification cycles allowing for quantification of methylation in the log-linear phase of amplification and directly demonstrates its sensitivity and potential application in methylation detection in patient samples. 15
Multiplexing allows for a more reliable comparison between methylated and unmethylated status for each individual sample as the input DNA is analyzed simultaneously (Supplementary Fig. 3A) . Such multiplex reaction can be extended to a multi-gene analysis in the same reaction (data not shown). Direct visual inspection of donor quenching facilitates such a quick qualitative read out (Supplementary Fig.  20 3B). Unlike most standard methylation detection techniques that are limited by the capacity of the number of wells or detectors, MS-qFRET can screen thousands of samples at a time using a standard UV scanner. Also, the feature of endpoint detection in a small detection volume renders MS-qFRET compatible with the standard microplate reader and can be straightforwardly implemented in the next-generation 1,536-well format for high-throughput screening.
Application of MS-qFRET to cancer cell lines, MDS samples and sputum samples demonstrates utility in a clinical setting. By quantifying methylation in cell 5 lines and MDS patient samples, the application of MS-qFRET in monitoring cancer therapy is highlighted (Fig. 3C and Fig. 3D) . A common method to assess gene specific response to epigenetic treatment is through gel electrophoresis and therefore is not quantitative (Cameron et al. 1999; Gore et al. 2006a) . One advantage to MSqFRET is easy adoption into current MSP methodology. Additionally, by assigning 10 values through a q-score, MS-qFRET allows for a greater resolving capability in monitoring methylation reversal by being more sensitive and quantitative (Fig. 3) .
While one would expect decreased DNA methylation following the treatment with azacitidine, this is not observed in all patients, since some will have disease progression despite epigenetic treatment. In this study, there are not enough patient 15 samples to test the correlation of a patient's gene specific demethylation to corresponding clinical response, but anticipate that MS-qFRET may provide an avenue to answer such questions in ongoing and future clinical trials using epigenetic therapy.
The ability to use MS-qFRET for methylation detection in sputum samples (Fig.  20   4) highlights the feasibility for its future application in routine processing of patient samples with low amounts of DNA such as serum, stool and urine. Based on prior studies (Machida et al. 2006) , we estimate the DNA concentration in the sputum samples to vary from 30 pg/µL to 200 pg/µL. However, this detection is even more challenging since DNA from the tumor or affected tissues represents a small minority of the sample, with most DNA coming from reactive inflammatory cells. Clear demonstration of methylation in patient sputum is observed when compared to the background noise using MS-qFRET (Fig. 4B) . Since MS-qFRET is ultrasensitive, it will 5 be a concern that the incidence of false positives will be high. Generally, false positives (for methylation) can arise from non-specific amplification which can best be avoided by careful design of primers and setting right controls. MS-qFRET uses the inherent low background signal for a QD-FRET sensor that allows setting of a robust cut-off that can help reduce false positives (Fig 4C) . As demonstrated in the analysis 10 of methylation in sputum, 17 patients did not show methylation of PYCARD. These results were consistent with the nested results. Further, MS-qFRET analysis of CDKN2b and CDKN2a in the same sputum samples corresponded with the nested PCR data highlighting the high sensitivity of this technique in the absence of false positives. The technique is therefore capable of providing equivalent results as the 15 nested approach without the need for an additional PCR step (Fig. 4, Supplementary   Fig. 4) .
The numerous attributes of QD-FRET nanosensors make them ideal for detecting and quantifying methylation. While the technique in its current setup has been described to be a multistep process, it can eventually be reduced to a single step 20 process wherein the analysis can be made through the plate spectrophotometer and the results analyzed using software that can read and analyze the spectral curves. The real advantage therefore lies in the high signal to noise ratio of QD-FRET sensors that Cold Spring Harbor Laboratory Press on September 29, 2017 -Published by genome.cshlp.org Downloaded from allow for eliminating an extra PCR step, thereby increasing throughput in detection and has the potential for being fully automated. In addition, MS-qFRET is fully compatible with standard MSP (Herman et al. 1996) , and significantly transforms this most widely used technology for methylation detection to become a quantitative, high-throughput and ultrasensitive format via the end-labeling of existing MSP primers and the 5 inclusion of off-the-shelf QDs for fluorescent measurements. Hence, MS-qFRET is a method that can be readily adopted by a broad range of laboratories and will likely have an immediate impact on basic and clinical research.
Methods 10

DNA Isolation and Bisulfite Modification. In vitro methylated DNA (IVD) was
obtained from treatment of leukocyte DNA with SSSI methyltransferase. Peripheral blood normal lymphocytes (NL) were isolated from blood from the same normal volunteer, sputum samples were obtained from patients with a known smoking history, and bone marrow aspirate samples were obtained from MDS patients. RKO cells were 15 cultured and treated with 1 µM DAC and collected at fixed time points. 1 µM DAC was added to the cells every 24 hrs. DNA extraction and bisulfite modification was performed as previously described (Herman et al. 1996) .
Primers. The primer sequences are described in Table 1 and have been previously 20 validated (Herman et al. 1996; Machida et al. 2006) . The primers for MS-qFRET were replicates of those used in standard MSP except for 5' labeling of the forward primer with a final extension cycle of 72°C for 5 min. Annealing temperature was 58°C for CDKN2b and TMS-1. Unmethylated (NL), Methylated controls (IVD) and water controls (no template added) were utilized. All PCR products (5 µl) were loaded onto a 2% agarose gel, stained with GelStar (Lonza) and directly visualized under UVillumination. The nested MSP procedure required a 2 step PCR process and was 10 performed as previously described (Machida et al. 2006 ).
MS-qFRET.
a. General Procedure. PCR with labeled primers was run as previously described. genomic DNA is subject to sodium bisulfite conversion, wherein unmethylated cytosines are converted to uracil while methylated cytosines remain unaffected. In step 2, DNA is amplified using PCR wherein the forward and reverse primers are labeled with a biotin 5 (black dot) and a fluorophore (red dot) respectively. In step 3, the resulting labeled-PCR product is captured by streptavidin functionalized QDs through streptavidin-biotin affinity. Finally, in step 4, upon suitably exciting the QD, the nanoassembly formed allows for FRET to occur between the QD donor and the fluorophore acceptor.
Consequently, the labeled-PCR products are detected by emissions of fluorophores 10 accompanied by quenching of QDs to reveal the status of DNA methylation. bursts for the acceptor (Cy5), and was plotted for the entire time duration (3 separate preparations and 3 separate runs of 100 s) for 1/10, 1/100, 1/1,000 and 1/10,000 and 0 methylated/ unmethylated CDKN2a alleles (IVD/NL). The standard error increases with increased dilution due to sampling effects. Nonetheless, signal from 15 pg of methylated DNA in 150 ng NL (1/10,000 methylated/ unmethylated) is significantly higher than the NL control (background).
Supplementary Figure 2.
Real-time PCR data for methylation changes at CDKN2b 5 using MS-qFRET in 6 MDS patients undergoing epigenetic therapy. Percent methylation is calculated for each patient based on the C t value. Results presented are from the average of triplicate results and have been normalized against a standard curve generated using IVD and NL serial dilutions. MS-qFRET results presented in Figure 3D are consistent with these results. 10
Supplementary Figure 3. Detection through Multiplex Reactions and Direct
Visualization. In conventional MSP methods (Eads et al. 2000; Herman et al. 1996) , each methylated and unmethylated reaction is performed in separate reaction tubes.
Using MS-qFRET, simultaneous analysis of both unmethylated and methylated 15 reactions in a single tube was achieved by uniquely labeling unmethylated and methylated CDKN2a primers with Cy5 and Alexa594, respectively. QD585 serves as a common donor to Cy5 and Alexa594 (Supplementary Table 1 ). As shown in Supplementary Figure 3A, for the water control, no emission was observed from the acceptor (Cy5). The only peak seen was at 585 nm which corresponded with the 20 donor (quantum dot) emission. For unmethylated DNA only Cy5 emission was observed while for methylated DNA had only Alexa594 emission. Upon analyzing a mixture of both targets, Cy5 and Alexa594 peaks were simultaneously detected, confirming the presence of both unmethylated and methylated alleles.
Recognizing that often a subjective, and yet rapid, determination of methylation is necessary, MS-qFRET can be adapted such that methylation can be detected through simple fluorescent visualization. In both IVD and NL, a qualitative, visual 5 analysis of methylation of CDKN2b, CDKN2a and TMS-1 promoters (Herman et al. 1996; Machida et al. 2006) for CDKN2b and CDKN2a for 8 patients indicate the presence of only unmethylated products. For CDKN2b, no methylated bands were detected even after using nested MSP. However, for CDKN2a, gel from nested MSP products detects methylation in Patient 1, 3, 6, 7, 8, 10, 12, 14, 16, 17 and 19 
